Formulation comprising extracellular vesicles, method for producing the same, and uses thereof
Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.
1 . A method of treating an inflammatory disease in a subject, comprising administering to the subject an effective amount of a formulation comprising an extracellular vesicle (EV) derived from a mesenchymal stem cell and curcumin encapsulated in the EV, wherein the mesenchymal stem cell is isolated from Wharton jelly of umbilical cord and is CD29 + , CD34 − , CD44 + and CD73 + , wherein the inflammatory disease is psoriasis, and wherein the formulation is prepared by:
(a) culturing the mesenchymal stem cell in the presence of aspirin;
(b) culturing the mesenchymal stem cell obtained in step (a) under 1% to 5% O 2 and in serum free medium;
(c) isolating the EV from the cultured mesenchymal stem cell obtained in step (b); and
(d) incubating the isolated EV obtained in step (c) with curcumin under a condition of pH 6.0 to 10.0 to encapsulate the curcumin in the isolated EV obtained in step (c).
2 . The method of claim 1 , wherein the formulation is administered to the subject via a route selected from the group consisting of topical, intraconjunctival, intranasal, intratracheal, oral, intraspinal, intravenous, intraarterial, intramuscular, subcutaneous, intraarticular, intraventrical, intracerebroventricular, intraperitoneal injection and intra-middle ear administration.
3 . The method of claim 1 , wherein the subject is a human.